17,261 trials
Asthma
Primary: Cmax of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg — 250; 365; 168; 197…
Asthma
Primary: Change From Baseline in Daytime Composite Symptom Score — 3.1; 2.8; 2.6; -0.7 units on a scale
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Best Objective Response — 2 Percentage of participants
Healthy Subjects
Primary: Cmax of Dihydroergotamine After MAP0004 and IV DHE Administration in Smokers Versus Non-smokers — 1282.059; 2550.727; 60046.128; 48428.635 pg/ml
Neoplasms, Unknown Primary
Primary: Progression Free Survival — 3.7 months
Esophagitis
Primary: Change in Eosinophil Numbers Per High Power Field Proximally and Distally Between Baseline and Post-treatment and Between Both Groups — 0.6; -7.5 perecentage of eos per…
Infection, Human Immunodeficiency Virus
Primary: Number of Participants Who Achieved HIV-1 RNA <400 Copies (c)/Milliliter (mL) or at Least 0.7 log10 c/mL Below Their Baseline Value at Day 11 — 21; 23 Participants
Rheumatoid Arthritis
Primary: Percentage of Patients With a Positive Immune Response to Tetanus Toxoid Adsorbed Booster Vaccine — 39.1; 42.3 Percentage of patients
Neoplasm, Unknown Primary
Primary: Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death — 12.6 months
Ocular Hypertension · Glaucoma
Primary: Change From Baseline in Average Eye Intraocular Pressure (IOP) — 25.350; 25.318; 25.341; 24.650 Millimeters of Mercury (mmHg)
Head and Neck Cancer · Precancerous/Nonmalignant Condition
Primary: Number of Patients Achieving Complete or Partial Response 4 Months After Completion of Study Treatment — 32 participants
HIV-1
Primary: Change From Baseline in Human Immunodeficiency Virus-1 (HIV-1) Viral Load at Day 8 — 4.57; 4.39; 4.41; 4.38 log10 copies/mL
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Average Eye Intraocular Pressure (IOP) — 25.88; 25.18; 25.39; 25.73 Millimeters of Mercury (mmHg)
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · Recurrent Metastatic Squamous Neck Cancer With Occult Primary · Recurrent Squamous Cell Carcinoma of the Hypopharynx
Primary: Overall Response Rate — 1; 8 participants
Liver Cancer
Primary: Number of Subjects Experiencing Adverse Events — 2 participants